Paysign (NASDAQ:PAYS) Sees Unusually-High Trading Volume After Earnings Beat

Key Points

• Paysign beat Q3 estimates: EPS was $0.11 versus $0.09 expected, while revenue reached a record $30.8 million, up 42.6% year over year. Operating margin more than tripled to 23.8%, and pharma revenue more than doubled.
• FY 2026 earnings guidance disappointed: The company forecast EPS of $0.37–$0.38, below the $0.51 analyst consensus, despite revenue guidance of $114–$117 million. The outlook may have contributed to the share price decline after results.
• Trading volume rose 26% above its average to about 932,000 shares as the stock traded below its prior close.

Shares of Paysign, Inc. (NASDAQ:PAYS - Get Free Report) saw an uptick in trading volume on Tuesday following a better than expected earnings announcement. Approximately 931,905 shares changed hands during mid-day trading, an increase of 26% from the average daily volume of 738,914 shares. The stock last traded at $10.8760 and had previously closed at $12.51.

The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $30.80 million during the quarter, compared to analysts' expectations of $29.02 million. Paysign had a return on equity of 30.13% and a net margin of 15.67%.

Key Stories Impacting Paysign

Here are the key news stories impacting Paysign this week:

• Positive Sentiment: Q3 revenue rose 42.6% year over year to a record $30.8 million, beating the $29.02 million consensus estimate. EPS of $0.11 also topped the $0.09 estimate, while operating margin more than tripled to 23.8%. Pharma revenue more than doubled. Paysign Q3 2026 results
• Neutral Sentiment: For FY 2026, Paysign forecast revenue of $114 million to $117 million, broadly around the $114.7 million consensus. It projected gross margin of 63.5% to 64.5%. 2026 revenue and margin outlook
• Negative Sentiment: The company’s FY 2026 EPS guidance of $0.37 to $0.38 is well below the $0.51 analyst consensus. That earnings outlook may have outweighed the quarterly beat and contributed to the stock’s decline. Paysign Q3 2026 earnings call transcript

Analyst Upgrades and Downgrades

PAYS has been the subject of a number of research reports. Weiss Ratings upgraded shares of Paysign from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Wall Street Zen downgraded shares of Paysign from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 16th. DA Davidson raised their target price on Paysign from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, September 30th. Barrington Research set a $15.00 price target on Paysign in a research note on Tuesday, August 11th. Finally, Lake Street Capital boosted their price objective on shares of Paysign from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, September 15th. Three equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $15.00.

Insider Buying and Selling at Paysign

In related news, CFO Jeffery Baker sold 35,000 shares of Paysign stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $12.62, for a total value of $441,700.00. Following the transaction, the chief financial officer owned 542,171 shares in the company, valued at $6,842,198.02. This trade represents a 6.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mark Newcomer sold 50,000 shares of the firm's stock in a transaction on Friday, October 9th. The stock was sold at an average price of $15.34, for a total transaction of $767,000.00. Following the completion of the sale, the chief executive officer owned 9,113,002 shares in the company, valued at $139,793,450.68. This represents a 0.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 294,904 shares of company stock valued at $3,844,124. Corporate insiders own 24.50% of the company's stock.

Institutional Investors Weigh In On Paysign

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Paysign in the 2nd quarter valued at about $25,219,000. Punch & Associates Investment Management Inc. bought a new position in Paysign during the second quarter worth $16,983,000. Renaissance Technologies LLC boosted its position in shares of Paysign by 17.4% during the first quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company's stock valued at $9,033,000 after buying an additional 227,300 shares during the last quarter. AWM Investment Company Inc. purchased a new position in Paysign in the second quarter valued at approximately $6,560,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Paysign by 16.8% in the first quarter. Dimensional Fund Advisors LP now owns 575,619 shares of the company's stock valued at $3,396,000 after acquiring an additional 82,736 shares during the period. Institutional investors and hedge funds own 25.89% of the company's stock.

Paysign Stock Performance

The firm has a 50-day moving average price of $13.87 and a 200 day moving average price of $8.60. The stock has a market capitalization of $616.43 million, a P/E ratio of 41.97 and a beta of 0.92.

Paysign Company Profile

Paysign, Inc NASDAQ: PAYS is a financial technology company that provides payment and prepaid card solutions for businesses and organizations. Its platform supports the issuance, distribution and management of branded prepaid cards and other electronic payment products, helping clients deliver funds to consumers and program participants.

The company serves several specialized markets, including plasma collection centers, pharmaceutical manufacturers and other healthcare-related organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.